Vincristine negatively affects musculoskeletal growth in young mice - Takeaways - MDSpire

Vincristine negatively affects musculoskeletal growth in young mice

  • By

  • Nicholas A. Jamnick

  • Patrick D. Livingston

  • Caleb J. Gammon

  • Natalia M. Weinzierl

  • Leah J. Novinger

  • Douglas J. Adams

  • Andrea Bonetto

  • November 18, 2025

  • 0 min

Share

  • 1

    Vincristine, a common pediatric chemotherapy, negatively impacts musculoskeletal growth in young mice during critical developmental periods.

  • 2

    The study utilized 4-week-old male C57BL/6J mice to evaluate the effects of vincristine on muscle development over a five-week treatment period.

  • 3

    Vincristine treatment resulted in significant musculoskeletal defects, including muscle atrophy and impaired cellular integrity.

  • 4

    The research highlights the need for understanding vincristine's long-term effects on pediatric patients' musculoskeletal health.

  • 5

    Findings aim to inform targeted interventions that preserve musculoskeletal health while maintaining effective cancer treatment.

Original Source(s)

Vincristine negatively affects musculoskeletal growth in young mice

  • by Nicholas A. Jamnick, Patrick D. Livingston, Caleb J. Gammon, Natalia M. Weinzierl, Leah J. Novinger, Douglas J. Adams, Andrea Bonetto

  • November 18, 2025

Related Content

Advances in Hodgkin Lymphoma Treatment: Clinical Considerations for Managing Toxicities in Nivolumab-AVD Therapy

One of the most promising developments in advanced-stage Hodgkin lymphoma is the nivolumab-AVD regimen, which combines nivolumab with doxorubicin, vinblastine, and dacarbazine. This article provides practical knowledge for advanced practitioners to effectively manage the most common toxicities associated with nivolumab-AVD.

Novel PTRH2::ALK Fusion in ALK-positive Histiocytosis Presenting as a Liver Abscess in an Infant: A Case Study

This Week’s CGT News: Novo’s Parkinson’s Pivot

Novo Nordisk’s Parkinson’s cell therapy finds a new home at Cellular Intelligence, while base editing, prime editing, and large-insertion genome writing push forward

  • May 18, 2026

  • 7 min